The lifeblood of scientific discovery is information. Unless research findings are published and reach the medical community, they are of little value. However, there are problems with the present method of publishing medical research results. Peer review, a process by which experimenters review each other's work in order to weed out poor research, may not catch important errors. The results from some clinical research trials with negative findings may not be published and that also represents a serous problem. Paxil, a drug that some believe leads to juvenile suicides is used to illustrate this issue. A major Paxil trial with a positive result was published and presented at medical meetings, but a similar trial with a negative result ended up with no publication. The case illustrates that a drug's safety and efficacy problems can be deliberately hidden from the medical profession and the public. There are therefore calls for a clinical trial registry, which would contain the results of all clinical research investigations whether or not published in a journal. In addition, an innovative plan by faculty members of the London School of Hygiene and Tropical Medicine is used to suggest a radically way to change the current publication system.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Chapter 18 — Publishing
Cited References
Altman D, Goodman S, Schroter S. How statistical expertise is used in medical research. JAMA 2002:287;2817–2820.
Chan A, Altman D. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. Br Med J 2005:330;753.
Chan A, Hróbjartsson A, Haahr M, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004:291;2457–2465.
Diamond G, Bax L, Kaul S. Uncertain effects of Rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. Epub http://www.annals.org/cgi/content/abstract/0000605—200710160—00182v1 Aug 7, 2007.
Home P, Pocock S, Beck-Nielsen H. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. New Engl J Med 2007:357;28–38.
Kassirer J. Reflections on medical journals: has progress made them better? Ann Intern Med 2002:137;46–48.
May G, DeMets D, Friedman L, et al. The randomized clinical trial: bias in analysis. Circulation 1981:64;669–673.
Nissen S, Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007:356;2457–2471.
Science and technology: sloppy stats shame science. The Economist June 5, 2004:371;79.
Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials 2006:1;e6.
General References
Altman D. Poor-quality medical research: what can journals do? JAMA 2002:287;2765–2767.
Altman L. When peer review produces unsound science. New York Times June 11, 2002:F6.
Altman L. The doctor's world: for science's gatekeepers, a credibility gap. New York Times May, 2006:F1.
De Angelis C, Drazen J, Frizelle F, et al. Clinical trial registration: a statement from the nternational Committee of Medical Journal Editors. New Engl J Med 2004:351;1250–1251
Editorial. For truth in drug trial reporting. New York Times June 20, 2004:412.
Editorial. Manipulating a journal article. New York Times Dec 11, 2005 p 4.11.
Fontanarosa P, Flanagin A, DeAngelis C. Reporting conflicts of interest, financial aspects of esearch, and role of sponsors in funded studies. JAMA 2005:294;110–111.
Gorner P. Medical studies make news, worthy or not; researchers see flaws in coverage. Chicago ribune June 5, 2002:110.
Harris G. New York State official sues drug maker over test data. New York Times June 3, 2004:A1.
Jefferson T. Effects of editorial peer review: a systematic review. JAMA 2002:287;2784–2786.
Korn D, Ehringhaus S. Principles for strengthening the integrity of clinical research. PLoS Clin Trials 2006:1;e1.
Meier B. Contracts keep drug research out of reach. New York Times Nov 29, 2004;A1.
Meier B. Two studies, two results, and a debate over a drug. New York Times June 3, 2004:C1.
Rennie D. Fourth international congress on peer review in biomedical publications. JAMA 2002:287;2759–2760.
Specter M. Quality control of published medical studies debated. Washington Post May 15, 1989:A20.
Steinbrook R. Registration of clinical trials — voluntary or mandatory? New Engl J Med 2004:351;1820–1822.
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media B.V
About this chapter
Cite this chapter
(2009). Publishing – Getting the Word Out to Doctors. In: It's Great! Oops, No It Isn't. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8907-7_18
Download citation
DOI: https://doi.org/10.1007/978-1-4020-8907-7_18
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-8906-0
Online ISBN: 978-1-4020-8907-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)